Dozen drugs win Nov PBS listing

The second last round of PBS listings for 2025 has seen 12 drugs win reimbursement from November, seven of them new listings.

Eligible Australians living with advanced unresectable hepatocellular carcinoma (HCC), the most common type of primary liver cancer, can now access AstraZeneca's Imfinzi and Imjudo duo - the first dual immunotherapy combination option funded on the PBS.

The treatment known as the Stride regimen is Imfinzi in combination with a single dose of Imjudo, followed by Imfinizi monotherapy. It is funded for adult patients with unresectable HCC who have not received prior treatment with a PD1/PD-L1 inhibitor.